All News

The panel recommended that baseline PSA testing be done in Black men between the ages of 40 to 45.

ZH9 is a proprietary bacterial immunotherapy administered to patients via a single-dose intravesical induction regimen.

“99mTc‐PSMA-SPECT/CT is useful in the primary diagnosis of prostate cancer,” the authors wrote.

"The data from the QUILT 3.032 Quality of Life study suggest that many patients not only have a durable response but also report no decline in physical function, which is very important for these patients,” says Karim Chamie, MD.

Prior authorizations for medical care will become quicker and easier, while saving money, according to the Centers for Medicare & Medicaid Services.

“The results suggest there is a clinically meaningful population of patients who can experience a long-term survival benefit from tivozanib over sorafenib,” said Kathryn E. Beckermann, MD, PhD.

“The more informed the patients are, the more likely they are to participate in decision making…Patient engagement in decisions reduces decisional regret and fosters patient satisfaction with treatment outcomes,” the researchers wrote.

"At MIU, we host many ancillary services, including complete ultrasound services, UroCuff, urodynamics, PTNS [percutaneous tibial nerve stimulation], full laboratory and pathology services, Xofigo [radium-223]," says Jason M. Hafron, MD.

“This data supports the clinical benefit of 177Lu-PSMA-617 in real-world clinical practice,” the researchers wrote in their poster conclusion.

"It adds to the evidence base that is building that shows that improving your fitness levels is a positive thing to do to reduce your risk of developing prostate cancer," says Kate A. Bolam Enarsson, PhD.

“Prostatic extracellular vesicles represent a promising biomarker with the potential for reduction of false positive rate in men with elevated PSA following mpMRI,” the authors wrote.

“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.

According to statistics provided by the AUA, 385 medical students and other applicants were matched across 148 urology residency training programs nationwide.

"This study identifies a new target for VTE prevention," writes Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.

Data revealed that 49% of prostate cancer signups in clinical trials were among patients newly diagnosed with cancer, compared with 32% among patients with other solid tumors.

The applications in the EU and Japan are both based on findings from the phase 3 EV-302 trial.

"I predict 2024 will be a banner year for progress in the management of [NMIBC], and not only will we be moving the needle but also turning up the volume in this historically quiet space," writes Michael S. Cookson, MD, MMHC, FACS.

PSMA-PET imaging has successfully disrupted the prostate cancer paradigm and experts agree that unleashing the full potential of this breakthrough requires a multidisciplinary approach.

“Our study provides real-world recurrence and survival rates, [however], a major limitation is the retrospective nature of the analysis,” wrote the investigators, led by Viktor Gruenwald, MD, PhD.

Iterum plans to resubmit a New Drug Application for oral sulopenem for the treatment of patients with uUTi in Q2 of 2024.

The clearance will initiate the phase 2 CELLVX-230 trial, which will assess the therapy in patients with prostate cancer with a high risk of recurrence following prostatectomy.

The application is based on findings from the phase 2 DESTINY-PanTumor02 trial.

Patients in the subcutaneous arm (n = 242) achieved a geometric mean Cavgd28 of 77.373μl/mL (90% CI, 74.555-80.297) compared with 36.875 μl/mL (90% CI, 35.565-38.235) in the IV arm (n = 245), for a geometric mean ratio of 2.098 μl/mL (90% CI, 2.001-2.200).

Overall, the pathological complete response rate among patients who received APL-1202 plus tislelizumab was 39%, compared with 21% among those who received tislelizumab alone.

“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.

Patient subgroups that favored nivolumab vs placebo included patients with sarcomatoid features (HR, 0.42; 95% CI, 0.17-1.07), PD-L1 expression of 1% or greater (HR, 0.53; 95% CI, 0.22-1.29), and those with lower limit of normal hemoglobin at baseline (HR, 0.49; 95% CI, 0.25-1.49).

“The benefit of enfortumab vedotin plus pembrolizumab in all prespecified subgroups was consistent with the overall patient population,” said Michiel S. Van Der Heijden, MD, PhD.

Belzutifan extended the time to disease progression and was associated with improvements in QoL scores compared with everolimus.

Adjuvant pembrolizumab prolonged overall survival versus placebo in certain patients with clear cell renal cell carcinoma.

Adjuvant pembrolizumab reduced the risk of disease recurrence or death, but did not improve overall survival, compared with observation in patients with urothelial carcinoma.